[go: up one dir, main page]

MXPA02003118A - Metodos para reducir los niveles de glucosa y trigliceridos en suero, y para inhibir la angiogenesis utilizando acidos indolalcanoicos substituidos. - Google Patents

Metodos para reducir los niveles de glucosa y trigliceridos en suero, y para inhibir la angiogenesis utilizando acidos indolalcanoicos substituidos.

Info

Publication number
MXPA02003118A
MXPA02003118A MXPA02003118A MXPA02003118A MXPA02003118A MX PA02003118 A MXPA02003118 A MX PA02003118A MX PA02003118 A MXPA02003118 A MX PA02003118A MX PA02003118 A MXPA02003118 A MX PA02003118A MX PA02003118 A MXPA02003118 A MX PA02003118A
Authority
MX
Mexico
Prior art keywords
methods
triglyceride levels
serum glucose
reducing serum
inhibiting angiogenesis
Prior art date
Application number
MXPA02003118A
Other languages
English (en)
Inventor
Janet Sredy
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of MXPA02003118A publication Critical patent/MXPA02003118A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describen metodos para reducir niveles de glucosa y trigliceridos en suero y para inhibir angiogenesis, los metodos comprenden la administracion de acidos indolalcanoicos sustituidos a pacientes que requeiran de tal tratamiento. Se describen tambien compuestos utiles en el tratamiento de angiogenesis, hiperglucemia, hiperlipidemia y complicaciones cronicas que se originan de diabetes mellitus. Tambien se describen composiciones farmaceuticas que contienen los compuestos.
MXPA02003118A 1998-12-01 1999-12-01 Metodos para reducir los niveles de glucosa y trigliceridos en suero, y para inhibir la angiogenesis utilizando acidos indolalcanoicos substituidos. MXPA02003118A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11039598P 1998-12-01 1998-12-01
PCT/US1999/028483 WO2000032180A2 (en) 1998-12-01 1999-12-01 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituted indolealkanoic acids

Publications (1)

Publication Number Publication Date
MXPA02003118A true MXPA02003118A (es) 2004-04-21

Family

ID=22332786

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003118A MXPA02003118A (es) 1998-12-01 1999-12-01 Metodos para reducir los niveles de glucosa y trigliceridos en suero, y para inhibir la angiogenesis utilizando acidos indolalcanoicos substituidos.

Country Status (30)

Country Link
US (5) US6555568B1 (es)
EP (1) EP1135124B1 (es)
JP (1) JP2002531398A (es)
KR (1) KR20010086075A (es)
CN (1) CN1368883A (es)
AP (1) AP2001002146A0 (es)
AT (1) ATE265210T1 (es)
AU (1) AU770925B2 (es)
BG (1) BG105531A (es)
BR (1) BR9915882A (es)
CA (1) CA2385845A1 (es)
CZ (1) CZ20011864A3 (es)
DE (1) DE69916881T2 (es)
DZ (1) DZ2953A1 (es)
EE (1) EE200100296A (es)
HK (1) HK1046372A1 (es)
HU (1) HUP0104953A3 (es)
ID (1) ID30037A (es)
IL (1) IL143247A0 (es)
MX (1) MXPA02003118A (es)
NO (1) NO20012690L (es)
OA (1) OA12035A (es)
PL (1) PL349016A1 (es)
SK (1) SK7352001A3 (es)
TN (1) TNSN99224A1 (es)
TR (1) TR200101539T2 (es)
TW (1) TW584560B (es)
WO (1) WO2000032180A2 (es)
YU (1) YU40101A (es)
ZA (1) ZA200104126B (es)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138711A0 (en) * 1998-03-31 2001-10-31 Inst Pharmaceutical Discovery Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
WO2001085983A2 (en) * 2000-05-09 2001-11-15 The Institute For Pharmaceutical Discovery Llc Methods for testing compounds useful for treating diabetic complications
ES2290318T3 (es) 2001-06-20 2008-02-16 Wyeth Derivados sustituidos de acido indolico como inhibidores del inhibidor del activador del plasminogeno-1 (pai-1).
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2004052855A2 (en) 2002-12-10 2004-06-24 Wyeth Substituted 3-carbonyl-1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2006514640A (ja) 2002-12-10 2006-05-11 ワイス プラスミノゲンアクティベータインヒビターのインヒビターとしての置換３−アルキル及び３−アリールアルキル１ｈ−イル酢酸誘導体
MXPA05006287A (es) 2002-12-10 2005-09-08 Wyeth Corp Derivados de acido indoloxo-acetilaminoacetico sustituidos como inhibidores del inhibidor del activador de plasminogeno 1 (pai-1).
AU2003296324A1 (en) 2002-12-10 2004-06-30 Wyeth Aryl, aryloxy, and alkyloxy substituted 1h-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP4828414B2 (ja) * 2003-04-28 2011-11-30 ニツポネツクス・インコーポレーテツド インドール酢酸誘導体および薬剤としてのそれらの使用
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
CA2568640C (en) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(ｐａｉ-1)의 조절제로서의옥사졸로-나프틸 산
BRPI0514572A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de tiazolo-naftila
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
JP2008521831A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
JP2008521829A (ja) * 2004-11-30 2008-06-26 プレキシコン，インコーポレーテッド Ｐｐａｒ活性化合物
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
NZ567162A (en) * 2005-09-07 2011-06-30 Plexxikon Inc 1, 3-disubstituted indole derivatives for use as PPAR modulators
MX2009000801A (es) 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) * 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
ES2032749T3 (es) 1985-11-07 1993-03-01 Pfizer Inc. Acidos oxoftalazinil-aceticos heterociclicos.
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4960785A (en) 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
US4996204A (en) 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) * 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
JP3195455B2 (ja) 1993-01-06 2001-08-06 ウェルファイド株式会社 キノリン−３−酢酸誘導体、その製造法と用途
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
AU7634694A (en) 1993-08-20 1995-03-21 University Of Medicine And Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
JPH09165371A (ja) * 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
IL138711A0 (en) 1998-03-31 2001-10-31 Inst Pharmaceutical Discovery Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
US6521659B2 (en) * 2000-03-02 2003-02-18 Institute For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
ATE265210T1 (de) 2004-05-15
YU40101A (sh) 2005-07-19
EP1135124A2 (en) 2001-09-26
CZ20011864A3 (cs) 2002-03-13
WO2000032180A2 (en) 2000-06-08
SK7352001A3 (en) 2002-06-04
CN1368883A (zh) 2002-09-11
HUP0104953A3 (en) 2002-08-28
US6555568B1 (en) 2003-04-29
AU770925B2 (en) 2004-03-11
EP1135124B1 (en) 2004-04-28
CA2385845A1 (en) 2000-06-08
EE200100296A (et) 2003-02-17
DE69916881T2 (de) 2005-02-03
DE69916881D1 (de) 2004-06-03
NO20012690L (no) 2001-07-27
AU2161600A (en) 2000-06-19
WO2000032180A3 (en) 2000-11-16
DZ2953A1 (fr) 2004-03-15
US20120065203A1 (en) 2012-03-15
ZA200104126B (en) 2002-05-21
US20060074114A1 (en) 2006-04-06
HUP0104953A2 (hu) 2002-07-29
US6964980B2 (en) 2005-11-15
US20030216452A1 (en) 2003-11-20
TR200101539T2 (tr) 2001-12-21
BR9915882A (pt) 2001-08-21
PL349016A1 (en) 2002-06-17
OA12035A (en) 2006-05-02
IL143247A0 (en) 2002-04-21
JP2002531398A (ja) 2002-09-24
TNSN99224A1 (fr) 2005-11-10
AP2001002146A0 (en) 2001-06-30
ID30037A (id) 2001-11-01
US20100324105A1 (en) 2010-12-23
BG105531A (en) 2001-12-31
NO20012690D0 (no) 2001-05-31
TW584560B (en) 2004-04-21
KR20010086075A (ko) 2001-09-07
HK1046372A1 (zh) 2003-01-10

Similar Documents

Publication Publication Date Title
AP2001002146A0 (en) Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted idolealkanoic acids
AP2000001929A0 (en) Substituted indolealkanoic acids.
BRPI0007820B8 (pt) formulações farmacêuticas agonistas de exendina e seus usos
EP2330092A3 (en) Medicament comprising steviol or isosteviol for the treatment of non-insulin dependent diabetes mellitus, hypertension and/or the metabolic syndrome
WO2001064205A3 (en) Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
UA32636C2 (uk) Засіб для зниження вмісту холестерину в сироватці крові людини
IL87149A (en) 6-Piperazinyl derivatives of purine and its 3- and 9-deaza isosteres, their preparation and pharmaceutical compositions containing them
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
IL72469A (en) Insulin derivatives,process for their preparation and pharmaceutical compositions for the treatment of diabetes mellitus
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
IL119971A0 (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2001000566A3 (en) Substituted phenoxyacetic acids
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
AU5917390A (en) Pharmaceutical composition for topic use for the therapeutical treatment of capillary fragility
HU901095D0 (en) Process for producing compound reducing extraction of gastric acid and pharmaceutical preparative containing said compound
WO2003000173A3 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
KR970706831A (ko) 당뇨병 치료용 약제 조성물(medicinal composition for diabetes)
KR920702225A (ko) 약학 조성물
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AU8019898A (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
WO2001051489A3 (en) Methods for lowering uric acid levels
EP1033133A4 (en) COMPOSITION FOR TREATING DIABETES AND METHOD FOR TREATING DIABETES
WO2000054760A3 (en) Bicyclo (3.3.1) nonenes useful for the treatment of diabetes and hypertriglyceridemia
IL99666A0 (en) Pharmaceutical compositions for the treatment of diabetes
MY138338A (en) Substituted indolealkanoic acids

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees